Hudson Bay Capital Management LP Purchases New Holdings in Abivax SA Sponsored ADR $ABVX

Hudson Bay Capital Management LP acquired a new position in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 91,062 shares of the company’s stock, valued at approximately $7,731,000.

A number of other institutional investors have also recently bought and sold shares of the business. Jefferies Financial Group Inc. purchased a new position in shares of Abivax in the 3rd quarter worth about $38,827,000. Kennedy Capital Management LLC raised its position in Abivax by 7.1% in the second quarter. Kennedy Capital Management LLC now owns 241,188 shares of the company’s stock worth $1,845,000 after acquiring an additional 15,997 shares during the period. Federated Hermes Inc. purchased a new position in Abivax in the third quarter valued at about $8,448,000. Persistent Asset Partners Ltd purchased a new position in Abivax in the third quarter valued at about $815,000. Finally, Atika Capital Management LLC bought a new position in shares of Abivax during the 3rd quarter valued at approximately $5,858,000. Institutional investors own 47.91% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ABVX shares. Jefferies Financial Group started coverage on shares of Abivax in a research note on Monday, March 16th. They set a “buy” rating and a $160.00 price target for the company. Wedbush began coverage on Abivax in a report on Tuesday, February 24th. They set an “outperform” rating and a $110.00 price objective for the company. Wall Street Zen downgraded Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Guggenheim restated a “buy” rating and issued a $175.00 target price on shares of Abivax in a research note on Thursday, December 18th. Finally, Citizens Jmp upped their price target on Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Abivax currently has a consensus rating of “Moderate Buy” and an average price target of $136.69.

Abivax Stock Down 2.2%

Shares of NASDAQ ABVX opened at $120.34 on Friday. The stock has a market capitalization of $9.52 billion, a P/E ratio of -28.79 and a beta of 1.00. Abivax SA Sponsored ADR has a one year low of $4.77 and a one year high of $148.83. The firm’s 50 day simple moving average is $119.35 and its two-hundred day simple moving average is $110.17. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.